TY - JOUR AU - Bach, L. A. PY - 2018 DA - 2018// TI - IGF-binding proteins JO - J Mol Endocrinol VL - 61 UR - https://doi.org/10.1530/JME-17-0254 DO - 10.1530/JME-17-0254 ID - Bach2018 ER - TY - JOUR AU - Roddam, A. W. AU - Allen, N. E. AU - Appleby, P. AU - Key, T. J. AU - Ferrucci, L. AU - Carter, H. B. PY - 2008 DA - 2008// TI - Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies JO - Ann Intern Med VL - 149 UR - https://doi.org/10.7326/0003-4819-149-7-200810070-00006 DO - 10.7326/0003-4819-149-7-200810070-00006 ID - Roddam2008 ER - TY - JOUR AU - Price, A. J. AU - Allen, N. E. AU - Appleby, P. N. AU - Crowe, F. L. AU - Travis, R. C. AU - Tipper, S. J. PY - 2012 DA - 2012// TI - Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition JO - Cancer Epidemiol Biomark Prev VL - 21 UR - https://doi.org/10.1158/1055-9965.EPI-12-0481-T DO - 10.1158/1055-9965.EPI-12-0481-T ID - Price2012 ER - TY - JOUR AU - Ho, G. Y. F. AU - Zheng, S. L. AU - Cushman, M. AU - Perez-Soler, R. AU - Kim, M. AU - Xue, X. PY - 2016 DA - 2016// TI - Associations of insulin and IGFBP-3 with lung cancer susceptibility in current smokers JO - J Natl Cancer Inst VL - 108 UR - https://doi.org/10.1093/jnci/djw012 DO - 10.1093/jnci/djw012 ID - Ho2016 ER - TY - JOUR AU - Yoon, Y. S. AU - Keum, N. AU - Zhang, X. AU - Cho, E. AU - Giovannucci, E. L. PY - 2015 DA - 2015// TI - Circulating levels of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and colorectal adenomas: a meta-analysis JO - Cancer Epidemiol VL - 39 UR - https://doi.org/10.1016/j.canep.2015.09.004 DO - 10.1016/j.canep.2015.09.004 ID - Yoon2015 ER - TY - JOUR AU - Adachi, Y. AU - Nojima, M. AU - Mori, M. AU - Yamashita, K. AU - Yamano, H. O. AU - Nakase, H. PY - 2017 DA - 2017// TI - Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study JO - World J Gastroenterol VL - 23 UR - https://doi.org/10.3748/wjg.v23.i19.3488 DO - 10.3748/wjg.v23.i19.3488 ID - Adachi2017 ER - TY - JOUR AU - Adachi, Y. AU - Nojima, M. AU - Mori, M. AU - Kubo, T. AU - Yamano, H. O. AU - Lin, Y. PY - 2019 DA - 2019// TI - Circulating insulin-like growth factor binding protein-3 and risk of gastrointestinal malignant tumors JO - J Gastroenterol Hepatol VL - 34 UR - https://doi.org/10.1111/jgh.14753 DO - 10.1111/jgh.14753 ID - Adachi2019 ER - TY - JOUR AU - Lin, C. AU - Travis, R. C. AU - Appleby, P. N. AU - Tipper, S. AU - Weiderpass, E. AU - Chang-Claude, J. PY - 2018 DA - 2018// TI - Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition JO - Int J Cancer VL - 143 UR - https://doi.org/10.1002/ijc.31650 DO - 10.1002/ijc.31650 ID - Lin2018 ER - TY - JOUR AU - Perez-Cornago, A. AU - Appleby, P. N. AU - Tipper, S. PY - 2017 DA - 2017// TI - Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition JO - Int J Cancer VL - 140 UR - https://doi.org/10.1002/ijc.30528 DO - 10.1002/ijc.30528 ID - Perez-Cornago2017 ER - TY - JOUR AU - Bradbury, K. E. AU - Appleby, P. N. AU - Tipper, S. J. AU - Key, T. J. AU - Allen, N. E. AU - Nieters, A. PY - 2019 DA - 2019// TI - Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition JO - Int J Cancer VL - 144 ID - Bradbury2019 ER - TY - JOUR AU - Chng, W. J. AU - Gualberto, A. AU - Fonseca, R. PY - 2006 DA - 2006// TI - IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma JO - Leuk Res VL - 20 ID - Chng2006 ER - TY - JOUR AU - Sprynski, A. C. AU - Hose, D. AU - Kassambara, A. AU - Vincent, L. AU - Jourdan, M. AU - Rossi, J. F. PY - 2010 DA - 2010// TI - Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation JO - Leuk Res VL - 24 ID - Sprynski2010 ER - TY - JOUR AU - Vishwamitra, D. AU - George, S. K. AU - Shi, P. AU - Kaseb, A. O. AU - Amin, H. M. PY - 2017 DA - 2017// TI - Type I insulin-like growth factor receptor signaling in hematological malignancies JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.12123 DO - 10.18632/oncotarget.12123 ID - Vishwamitra2017 ER - TY - JOUR AU - Xie, J. AU - Chen, X. AU - Zheng, J. AU - Li, C. AU - Stacy, S. AU - Holzenberger, M. PY - 2015 DA - 2015// TI - IGF-IR determines the fates of BCR/ABL leukemia JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0106-8 DO - 10.1186/s13045-015-0106-8 ID - Xie2015 ER - TY - JOUR AU - Medyouf, H. AU - Gusscott, S. AU - Wang, H. AU - Tseng, J. C. AU - Wai, C. AU - Nemirovsky, O. PY - 2011 DA - 2011// TI - High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by notch signaling JO - J Exp Med VL - 208 UR - https://doi.org/10.1084/jem.20110121 DO - 10.1084/jem.20110121 ID - Medyouf2011 ER - TY - JOUR AU - Lakshmikuttyamma, A. AU - Pastural, E. AU - Takahashi, N. AU - Sawada, K. AU - Sheridan, D. P. AU - DeCoteau, J. F. PY - 2008 DA - 2008// TI - Bcr-Abl induces autocrine IGF-1 signaling JO - Oncogene. VL - 27 UR - https://doi.org/10.1038/onc.2008.8 DO - 10.1038/onc.2008.8 ID - Lakshmikuttyamma2008 ER - TY - JOUR AU - Doepfner, K. T. AU - Spertini, O. AU - Arcaro, A. PY - 2007 DA - 2007// TI - Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway JO - Leukemia. VL - 21 UR - https://doi.org/10.1038/sj.leu.2404813 DO - 10.1038/sj.leu.2404813 ID - Doepfner2007 ER - TY - JOUR AU - Yaktapour, N. AU - Übelhart, R. AU - Schüler, J. AU - Aumann, K. AU - Dierks, C. AU - Burger, M. PY - 2013 DA - 2013// TI - Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2013-02-484386 DO - 10.1182/blood-2013-02-484386 ID - Yaktapour2013 ER - TY - JOUR AU - Shi, P. AU - Lai, R. AU - Lin, Q. AU - Iqbal, A. S. AU - Young, L. C. AU - Kwak, L. W. PY - 2009 DA - 2009// TI - IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells JO - Blood. VL - 114 UR - https://doi.org/10.1182/blood-2007-11-125658 DO - 10.1182/blood-2007-11-125658 ID - Shi2009 ER - TY - JOUR AU - Mitsiades, C. S. AU - Mitsiades, N. S. AU - McMullan, C. J. AU - Poulaki, V. AU - Shringarpure, R. AU - Akiyama, M. PY - 2004 DA - 2004// TI - Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors JO - Cancer Cell VL - 5 UR - https://doi.org/10.1016/S1535-6108(04)00050-9 DO - 10.1016/S1535-6108(04)00050-9 ID - Mitsiades2004 ER - TY - JOUR AU - Maris, C. AU - D’Haene, N. AU - Trépant, A. L. AU - Mercier, M. AU - Sauvage, S. AU - Allard, J. PY - 2015 DA - 2015// TI - IGF-IR: a new prognostic biomarker for human glioblastoma JO - Br J Cancer VL - 113 UR - https://doi.org/10.1038/bjc.2015.242 DO - 10.1038/bjc.2015.242 ID - Maris2015 ER - TY - JOUR AU - Khatib, A. M. AU - Siegfried, G. AU - Prat, A. AU - Luis, J. AU - Chrétien, M. AU - Metrakos, P. PY - 2001 DA - 2001// TI - Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions JO - J Biol Chem VL - 276 UR - https://doi.org/10.1074/jbc.M101725200 DO - 10.1074/jbc.M101725200 ID - Khatib2001 ER - TY - JOUR AU - LeRoith, D. AU - Werner, H. AU - Beitner-Johnson, D. AU - Roberts, C. T. PY - 1995 DA - 1995// TI - Molecular and cellular aspects of the insulin-like growth factor I receptor JO - Endocr Rev VL - 16 UR - https://doi.org/10.1210/edrv-16-2-143 DO - 10.1210/edrv-16-2-143 ID - LeRoith1995 ER - TY - JOUR AU - Ullrich, A. AU - Gray, A. AU - Tam, A. W. AU - Yang-Feng, T. AU - Tsubokawa, M. AU - Collins, C. PY - 1986 DA - 1986// TI - Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity JO - EMBO J VL - 5 UR - https://doi.org/10.1002/j.1460-2075.1986.tb04528.x DO - 10.1002/j.1460-2075.1986.tb04528.x ID - Ullrich1986 ER - TY - JOUR AU - Seino, S. AU - Bell, G. I. PY - 1989 DA - 1989// TI - Alternative splicing of human insulin receptor messenger RNA JO - Biochem Biophys Res Commun VL - 159 UR - https://doi.org/10.1016/0006-291X(89)92439-X DO - 10.1016/0006-291X(89)92439-X ID - Seino1989 ER - TY - JOUR AU - Evdokimova, V. AU - Tognon, C. E. AU - Benatar, T. AU - Yang, W. AU - Krutikov, K. AU - Pollak, M. PY - 2012 DA - 2012// TI - IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors JO - Sci Signal VL - 5 UR - https://doi.org/10.1126/scisignal.2003184 DO - 10.1126/scisignal.2003184 ID - Evdokimova2012 ER - TY - JOUR AU - Yee, D. PY - 2018 DA - 2018// TI - Anti-insulin-like growth factor therapy in breast cancer JO - J Mol Endocrinol VL - 61 UR - https://doi.org/10.1530/JME-17-0261 DO - 10.1530/JME-17-0261 ID - Yee2018 ER - TY - JOUR AU - Taniguchi, C. M. AU - Emanuelli, B. AU - Kahn, C. R. PY - 2006 DA - 2006// TI - Critical nodes in signalling pathways: insights into insulin action JO - Nat Rev Mol Cell Biol VL - 7 UR - https://doi.org/10.1038/nrm1837 DO - 10.1038/nrm1837 ID - Taniguchi2006 ER - TY - JOUR AU - Liu, D. AU - Rutter, W. J. AU - Wang, L. H. PY - 1993 DA - 1993// TI - Modulating effects of the extracellular sequence of the human insulin-like growth factor I receptor on its transforming and tumorigenic potential JO - J Virol VL - 67 UR - https://doi.org/10.1128/JVI.67.1.9-18.1993 DO - 10.1128/JVI.67.1.9-18.1993 ID - Liu1993 ER - TY - JOUR AU - Lee, J. H. AU - Choi, S. I. AU - Kim, R. K. AU - Cho, E. W. AU - Kim, I. G. PY - 2018 DA - 2018// TI - Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1 JO - Sci Rep VL - 8 UR - https://doi.org/10.1038/s41598-018-29142-x DO - 10.1038/s41598-018-29142-x ID - Lee2018 ER - TY - JOUR AU - Tahimic, C. G. AU - Long, R. K. AU - Kubota, T. AU - Sun, M. Y. AU - Elalieh, H. AU - Fong, C. PY - 2016 DA - 2016// TI - Regulation of ligand and shear stress-induced insulin-like growth factor 1 (IGF1) signaling by the integrin pathway JO - J Biol Chem VL - 291 UR - https://doi.org/10.1074/jbc.M115.693598 DO - 10.1074/jbc.M115.693598 ID - Tahimic2016 ER - TY - JOUR AU - Yin, Y. AU - Hua, H. AU - Li, M. AU - Liu, S. AU - Kong, Q. AU - Shao, T. PY - 2016 DA - 2016// TI - mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR JO - Cell Res VL - 26 UR - https://doi.org/10.1038/cr.2015.133 DO - 10.1038/cr.2015.133 ID - Yin2016 ER - TY - JOUR AU - Meyts, P. AU - Shymko, R. M. PY - 2000 DA - 2000// TI - Timing-dependent modulation of insulin mitogenic versus metabolic signalling JO - Novartis Found Symp VL - 227 ID - Meyts2000 ER - TY - JOUR AU - Accili, D. AU - Drago, J. AU - Lee, E. J. AU - Johnson, M. D. AU - Cool, M. H. AU - Salvatore, P. PY - 1996 DA - 1996// TI - Early neonatal death in mice homozygous for a null allele of the insulin receptor gene JO - Nat Genet VL - 12 UR - https://doi.org/10.1038/ng0196-106 DO - 10.1038/ng0196-106 ID - Accili1996 ER - TY - JOUR AU - Farabaugh, S. M. AU - Boone, D. N. AU - Lee, A. V. PY - 2015 DA - 2015// TI - Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation JO - Front Endocrinol (Lausanne) VL - 6 UR - https://doi.org/10.3389/fendo.2015.00059 DO - 10.3389/fendo.2015.00059 ID - Farabaugh2015 ER - TY - JOUR AU - Peiró, G. AU - Adrover, E. AU - Sánchez-Tejada, L. AU - Lerma, E. AU - Planelles, M. AU - Sánchez-Payá, J. PY - 2011 DA - 2011// TI - Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma JO - Mod Pathol VL - 24 UR - https://doi.org/10.1038/modpathol.2010.191 DO - 10.1038/modpathol.2010.191 ID - Peiró2011 ER - TY - JOUR AU - Law, J. H. AU - Habibi, G. AU - Hu, K. AU - Masoudi, H. AU - Wang, M. Y. AU - Stratford, A. L. PY - 2008 DA - 2008// TI - Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breastcancer subtypes and is related to poor survival JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-2755 DO - 10.1158/0008-5472.CAN-08-2755 ID - Law2008 ER - TY - JOUR AU - Creighton, C. J. AU - Casa, A. AU - Lazard, Z. AU - Huang, S. AU - Tsimelzon, A. AU - Hilsenbeck, S. G. PY - 2008 DA - 2008// TI - Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.4429 DO - 10.1200/JCO.2007.13.4429 ID - Creighton2008 ER - TY - JOUR AU - Yerushalmi, R. AU - Gelmon, K. A. AU - Leung, S. AU - Gao, D. AU - Cheang, M. AU - Pollak, M. PY - 2012 DA - 2012// TI - Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes JO - Breast Cancer Res Treat VL - 132 UR - https://doi.org/10.1007/s10549-011-1529-8 DO - 10.1007/s10549-011-1529-8 ID - Yerushalmi2012 ER - TY - JOUR AU - Mountzios, G. AU - Aivazi, D. AU - Kostopoulos, I. AU - Goldbogen, J. AU - Southall, B. PY - 2014 DA - 2014// TI - Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0091407 DO - 10.1371/journal.pone.0091407 ID - Mountzios2014 ER - TY - JOUR AU - Aleksic, T. AU - Verrill, C. AU - Bryant, R. J. AU - Han, C. AU - Worrall, A. R. AU - Brureau, L. PY - 2017 DA - 2017// TI - IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer JO - Br J Cancer VL - 117 UR - https://doi.org/10.1038/bjc.2017.337 DO - 10.1038/bjc.2017.337 ID - Aleksic2017 ER - TY - JOUR AU - Dale, O. T. AU - Aleksic, T. AU - Shah, K. A. AU - Han, C. AU - Mehanna, H. AU - Rapozo, D. C. PY - 2015 DA - 2015// TI - IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer JO - Carcinogenesis. VL - 36 UR - https://doi.org/10.1093/carcin/bgv053 DO - 10.1093/carcin/bgv053 ID - Dale2015 ER - TY - JOUR AU - Moreno-Acosta, P. AU - Vallard, A. AU - Carrillo, S. AU - Gamboa, O. AU - Romero-Rojas, A. AU - Molano, M. PY - 2017 DA - 2017// TI - Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma JO - Radiat Oncol VL - 12 UR - https://doi.org/10.1186/s13014-017-0856-2 DO - 10.1186/s13014-017-0856-2 ID - Moreno-Acosta2017 ER - TY - JOUR AU - Fruman, D. A. AU - Chiu, H. AU - Hopkins, B. D. AU - Bagrodia, S. AU - Cantley, L. C. AU - Abraham, R. T. PY - 2017 DA - 2017// TI - The PI3K pathway in human disease JO - Cell. VL - 170 UR - https://doi.org/10.1016/j.cell.2017.07.029 DO - 10.1016/j.cell.2017.07.029 ID - Fruman2017 ER - TY - JOUR AU - Giorgetti, S. AU - Ballotti, R. AU - Kowalski-Chauvel, A. AU - Tartare, S. AU - Obberghen, E. PY - 1993 DA - 1993// TI - The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro JO - J Biol Chem VL - 268 ID - Giorgetti1993 ER - TY - JOUR AU - Hua, H. AU - Kong, Q. AU - Zhang, H. AU - Wang, J. AU - Luo, T. AU - Jiang, Y. PY - 2019 DA - 2019// TI - Targeting mTOR for cancer therapy JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0754-1 DO - 10.1186/s13045-019-0754-1 ID - Hua2019 ER - TY - JOUR AU - Nitulescu, G. M. AU - Venter, M. AU - Nitulescu, G. AU - Nitulescu, G. AU - Ungurianu, A. AU - Juzenas, P. PY - 2018 DA - 2018// TI - The Akt pathway in oncology therapy and beyond JO - Int J Oncol VL - 53 ID - Nitulescu2018 ER - TY - JOUR AU - Qin, X. AU - Li, J. AU - Sun, J. AU - Liu, L. AU - Chen, D. AU - Liu, Y. PY - 2019 DA - 2019// TI - Low shear stress induces ERK nuclear localization and YAP activation to control the proliferation of breast cancer cells JO - Biochem Biophys Res Commun VL - 510 UR - https://doi.org/10.1016/j.bbrc.2019.01.065 DO - 10.1016/j.bbrc.2019.01.065 ID - Qin2019 ER - TY - JOUR AU - Zhu, H. AU - Wang, D. D. AU - Yuan, T. AU - Yan, F. J. AU - Zeng, C. M. AU - Dai, X. Y. PY - 2018 DA - 2018// TI - Multikinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis JO - Cancer Res VL - 78 UR - https://doi.org/10.1158/0008-5472.CAN-17-1548 DO - 10.1158/0008-5472.CAN-17-1548 ID - Zhu2018 ER - TY - JOUR AU - Straßburger, K. AU - Tiebe, M. AU - Pinna, F. AU - Breuhahn, K. AU - Teleman, A. A. PY - 2012 DA - 2012// TI - Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP JO - Dev Biol VL - 367 UR - https://doi.org/10.1016/j.ydbio.2012.05.008 DO - 10.1016/j.ydbio.2012.05.008 ID - Straßburger2012 ER - TY - JOUR AU - Ravid, D. AU - Maor, S. AU - Werner, H. AU - Liscovitch, M. PY - 2005 DA - 2005// TI - Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling JO - Oncogene. VL - 24 UR - https://doi.org/10.1038/sj.onc.1208337 DO - 10.1038/sj.onc.1208337 ID - Ravid2005 ER - TY - JOUR AU - Zhang, W. AU - Zong, C. S. AU - Hermanto, U. AU - Lopez-Bergami, P. AU - Ronai, Z. AU - Wang, L. H. PY - 2006 DA - 2006// TI - RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth JO - Mol Cell Biol VL - 26 UR - https://doi.org/10.1128/MCB.26.2.413-424.2006 DO - 10.1128/MCB.26.2.413-424.2006 ID - Zhang2006 ER - TY - JOUR AU - Kiely, P. A. AU - Sant, A. AU - O’Connor, R. PY - 2002 DA - 2002// TI - RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M201758200 DO - 10.1074/jbc.M201758200 ID - Kiely2002 ER - TY - JOUR AU - Li, H. AU - Baldwin, B. R. AU - Zahnow, C. A. PY - 2011 DA - 2011// TI - LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis JO - Mol Cancer VL - 10 UR - https://doi.org/10.1186/1476-4598-10-100 DO - 10.1186/1476-4598-10-100 ID - Li2011 ER - TY - JOUR AU - Sachdev, D. AU - Zhang, X. AU - Matise, I. AU - Gaillard-Kelly, M. AU - Yee, D. PY - 2010 DA - 2010// TI - The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival JO - Oncogene. VL - 29 UR - https://doi.org/10.1038/onc.2009.316 DO - 10.1038/onc.2009.316 ID - Sachdev2010 ER - TY - JOUR AU - Varkaris, A. AU - Gaur, S. AU - Parikh, N. U. AU - Song, J. H. AU - Dayyani, F. AU - Jin, J. K. PY - 2013 DA - 2013// TI - Ligand-independent activation of MET through IGF-1/IGF-1R signaling JO - Int J Cancer VL - 133 UR - https://doi.org/10.1002/ijc.28169 DO - 10.1002/ijc.28169 ID - Varkaris2013 ER - TY - JOUR AU - Jaquish, D. V. AU - Yu, P. T. AU - Shields, D. J. AU - French, R. P. AU - Maruyama, K. P. AU - Niessen, S. PY - 2011 DA - 2011// TI - IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration JO - Carcinogenesis. VL - 32 UR - https://doi.org/10.1093/carcin/bgr086 DO - 10.1093/carcin/bgr086 ID - Jaquish2011 ER - TY - JOUR AU - Svalina, M. N. AU - Kikuchi, K. AU - Abraham, J. AU - Lal, S. AU - Davare, M. A. AU - Settelmeyer, T. P. PY - 2016 DA - 2016// TI - IGF1R as a key target in high risk, metastatic medulloblastoma JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep27012 DO - 10.1038/srep27012 ID - Svalina2016 ER - TY - JOUR AU - Vella, V. AU - Malaguarnera, R. AU - Nicolosi, M. L. AU - Morrione, A. AU - Belfiore, A. PY - 2019 DA - 2019// TI - Insulin/IGF signaling and discoidin domain receptors: an emerging functional connection JO - Biochim Biophys Acta, Mol Cell Res VL - 1866 UR - https://doi.org/10.1016/j.bbamcr.2019.118522 DO - 10.1016/j.bbamcr.2019.118522 ID - Vella2019 ER - TY - JOUR AU - Azizi, R. AU - Salemi, Z. AU - Fallahian, F. AU - Aghaei, M. PY - 2019 DA - 2019// TI - Inhibition of didscoidin domain receptor 1 reduces epithelial-mesenchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines JO - J Cell Physiol VL - 234 UR - https://doi.org/10.1002/jcp.28552 DO - 10.1002/jcp.28552 ID - Azizi2019 ER - TY - JOUR AU - Cheng, J. AU - He, S. AU - Wang, M. AU - Zhou, L. AU - Zhang, Z. AU - Feng, X. PY - 2019 DA - 2019// TI - The caspase-3/PKCδ/Akt/VEGF-A signaling pathway mediates tumor repopulation during radiotherapy JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-3001 DO - 10.1158/1078-0432.CCR-18-3001 ID - Cheng2019 ER - TY - JOUR AU - Datta, K. AU - Nambudripad, R. AU - Pal, S. AU - Zhou, M. AU - Cohen, H. T. AU - Mukhopadhyay, D. PY - 2000 DA - 2000// TI - Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer JO - J Biol Chem VL - 275 UR - https://doi.org/10.1074/jbc.M909970199 DO - 10.1074/jbc.M909970199 ID - Datta2000 ER - TY - JOUR AU - Lyons, A. AU - Coleman, M. AU - Riis, S. AU - Favre, C. AU - O’Flanagan, C. H. AU - Zhdanov, A. V. PY - 2017 DA - 2017// TI - Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells JO - J Biol Chem VL - 292 UR - https://doi.org/10.1074/jbc.M117.792838 DO - 10.1074/jbc.M117.792838 ID - Lyons2017 ER - TY - STD TI - Yang Y, Yee D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. Cancer Res 2014;74:2295-305. ID - ref64 ER - TY - JOUR AU - Logan, S. AU - Pharaoh, G. A. AU - Marlin, M. C. AU - Masser, D. R. AU - Matsuzaki, S. AU - Wronowski, B. PY - 2018 DA - 2018// TI - Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-β uptake in astrocytes JO - Mol Metab VL - 9 UR - https://doi.org/10.1016/j.molmet.2018.01.013 DO - 10.1016/j.molmet.2018.01.013 ID - Logan2018 ER - TY - JOUR AU - Li, H. AU - Batth, I. S. AU - Qu, X. AU - Xu, L. AU - Song, N. AU - Wang, R. PY - 2017 DA - 2017// TI - IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights JO - Mol Cancer VL - 16 UR - https://doi.org/10.1186/s12943-016-0576-5 DO - 10.1186/s12943-016-0576-5 ID - Li2017 ER - TY - JOUR AU - Taliaferro-Smith, L. AU - Oberlick, E. AU - Liu, T. AU - McGlothen, T. AU - Alcaide, T. AU - Tobin, R. PY - 2015 DA - 2015// TI - FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.3023 DO - 10.18632/oncotarget.3023 ID - Taliaferro-Smith2015 ER - TY - JOUR AU - Kim, H. J. AU - Litzenburger, B. C. AU - Cui, X. AU - Delgado, D. A. AU - Grabiner, B. C. AU - Lin, X. PY - 2007 DA - 2007// TI - Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail JO - Mol Cell Biol VL - 27 UR - https://doi.org/10.1128/MCB.01315-06 DO - 10.1128/MCB.01315-06 ID - Kim2007 ER - TY - JOUR AU - Ye, X. AU - Tam, W. L. AU - Shibue, T. AU - Kaygusuz, Y. AU - Reinhardt, F. AU - Ng Eaton, E. PY - 2015 DA - 2015// TI - Distinct EMT programs control normal mammary stem cells and tumour-initiating cells JO - Nature. VL - 525 UR - https://doi.org/10.1038/nature14897 DO - 10.1038/nature14897 ID - Ye2015 ER - TY - JOUR AU - Yao, C. AU - Su, L. AU - Shan, J. AU - Zhu, C. AU - Liu, L. AU - Liu, C. PY - 2016 DA - 2016// TI - IGF/STAT3/NANOG/Slug signaling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer JO - Stem Cells VL - 34 UR - https://doi.org/10.1002/stem.2320 DO - 10.1002/stem.2320 ID - Yao2016 ER - TY - JOUR AU - Tominaga, K. AU - Shimamura, T. AU - Kimura, N. AU - Murayama, T. AU - Matsubara, D. AU - Kanauchi, H. PY - 2017 DA - 2017// TI - Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells JO - Oncogene. VL - 36 UR - https://doi.org/10.1038/onc.2016.293 DO - 10.1038/onc.2016.293 ID - Tominaga2017 ER - TY - JOUR AU - Xu, C. AU - Xie, D. AU - Yu, S. C. AU - Yang, X. J. AU - He, L. R. AU - Yang, J. PY - 2013 DA - 2013// TI - β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-4403 DO - 10.1158/0008-5472.CAN-12-4403 ID - Xu2013 ER - TY - JOUR AU - Chang, W. W. AU - Lin, R. J. AU - Yu, J. AU - Chang, W. Y. AU - Fu, C. H. AU - Lai, A. PY - 2013 DA - 2013// TI - The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors JO - Breast Cancer Res VL - 15 UR - https://doi.org/10.1186/bcr3423 DO - 10.1186/bcr3423 ID - Chang2013 ER - TY - JOUR AU - Steder, M. AU - Alla, V. AU - Meier, C. AU - Spitschak, A. AU - Pahnke, J. AU - Fürst, K. PY - 2013 DA - 2013// TI - DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling JO - Cancer Cell VL - 24 UR - https://doi.org/10.1016/j.ccr.2013.08.023 DO - 10.1016/j.ccr.2013.08.023 ID - Steder2013 ER - TY - JOUR AU - Meier, C. AU - Hardtstock, P. AU - Joost, S. AU - Alla, V. AU - Pützer, B. M. PY - 2016 DA - 2016// TI - p73 and IGF1R regulate emergence of aggressive cancer stem-like features via miR-885-5p control JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-15-1228 DO - 10.1158/0008-5472.CAN-15-1228 ID - Meier2016 ER - TY - JOUR AU - Chen, W. J. AU - Ho, C. C. AU - Chang, Y. L. AU - Chen, H. Y. AU - Lin, C. A. AU - Ling, T. Y. PY - 2014 DA - 2014// TI - Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling JO - Nat Commun VL - 5 UR - https://doi.org/10.1038/ncomms4472 DO - 10.1038/ncomms4472 ID - Chen2014 ER - TY - JOUR AU - Kim, I. G. AU - Kim, S. Y. AU - Choi, S. I. AU - Lee, J. H. AU - Kim, K. C. AU - Cho, E. W. PY - 2014 DA - 2014// TI - Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling JO - Oncogene. VL - 33 UR - https://doi.org/10.1038/onc.2013.373 DO - 10.1038/onc.2013.373 ID - Kim2014 ER - TY - JOUR AU - Aleksic, T. AU - Chitnis, M. M. AU - Perestenko, O. V. PY - 2010 DA - 2010// TI - Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-0052 DO - 10.1158/0008-5472.CAN-10-0052 ID - Aleksic2010 ER - TY - JOUR AU - Asmane, I. AU - Watkin, E. AU - Alberti, L. AU - Gao, S. AU - Thomas, P. H. AU - Turner, G. D. PY - 2012 DA - 2012// TI - Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2012.05.009 DO - 10.1016/j.ejca.2012.05.009 ID - Asmane2012 ER - TY - JOUR AU - Aslam, M. I. AU - Hettmer, S. AU - Abraham, J. AU - Latocha, D. AU - Soundararajan, A. AU - Huang, E. T. PY - 2013 DA - 2013// TI - Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar rhabdomyosarcoma JO - Mol Cancer Res VL - 11 UR - https://doi.org/10.1158/1541-7786.MCR-12-0598 DO - 10.1158/1541-7786.MCR-12-0598 ID - Aslam2013 ER - TY - JOUR AU - Sehat, B. AU - Tofigh, A. AU - Lin, Y. AU - Trocmé, E. AU - Liljedahl, U. AU - Lagergren, J. PY - 2010 DA - 2010// TI - SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor JO - Sci Signal VL - 3 UR - https://doi.org/10.1126/scisignal.2000628 DO - 10.1126/scisignal.2000628 ID - Sehat2010 ER - TY - JOUR AU - Deng, H. AU - Lin, Y. AU - Badin, M. PY - 2011 DA - 2011// TI - Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9 JO - Biochem Biophys Res Commun VL - 404 UR - https://doi.org/10.1016/j.bbrc.2010.12.038 DO - 10.1016/j.bbrc.2010.12.038 ID - Deng2011 ER - TY - JOUR AU - Packham, S. AU - Warsito, D. AU - Lin, Y. AU - Vasilcanu, D. AU - Strömberg, T. AU - Jernberg-Wiklund, H. PY - 2015 DA - 2015// TI - Nuclear translocation of IGF-1R via p150(Glued) and an importin-β/RanBP2-dependent pathway in cancer cells JO - Oncogene. VL - 34 UR - https://doi.org/10.1038/onc.2014.165 DO - 10.1038/onc.2014.165 ID - Packham2015 ER - TY - JOUR AU - Guerard, M. AU - Robin, T. AU - Perron, P. AU - Hatat, A. S. AU - David-Boudet, L. AU - Vanwonterghem, L. PY - 2018 DA - 2018// TI - Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI JO - Cancer Lett VL - 420 UR - https://doi.org/10.1016/j.canlet.2018.01.080 DO - 10.1016/j.canlet.2018.01.080 ID - Guerard2018 ER - TY - JOUR AU - Sarfstein, R. AU - Pasmanik-Chor, M. AU - Yeheskel, A. AU - Edry, L. AU - Shomron, N. AU - Warman, N. PY - 2012 DA - 2012// TI - Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells JO - J Biol Chem VL - 287 UR - https://doi.org/10.1074/jbc.M111.281782 DO - 10.1074/jbc.M111.281782 ID - Sarfstein2012 ER - TY - JOUR AU - Aleksic, T. AU - Gray, N. AU - Wu, X. AU - Rieunier, G. AU - Osher, E. AU - Mills, J. PY - 2018 DA - 2018// TI - Nuclear IGF1R interacts with regulatory regions of chromatin to promote RNA polymerase II recruitment and gene expression associated with advanced tumor stage JO - Cancer Res VL - 78 ID - Aleksic2018 ER - TY - JOUR AU - Warsito, D. AU - Sjöström, S. AU - Andersson, S. AU - Larsson, O. AU - Sehat, B. PY - 2012 DA - 2012// TI - Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF JO - EMBO Rep VL - 13 UR - https://doi.org/10.1038/embor.2011.251 DO - 10.1038/embor.2011.251 ID - Warsito2012 ER - TY - JOUR AU - Jamwal, G. AU - Singh, G. AU - Dar, M. S. AU - Singh, P. AU - Bano, N. AU - Syed, S. H. PY - 1865 DA - 1865// TI - Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/β-catenin signaling pathways JO - Biochim Biophys Acta, Mol Cell Res VL - 2018 ID - Jamwal1865 ER - TY - JOUR AU - Waraky, A. AU - Lin, Y. AU - Warsito, D. AU - Haglund, F. AU - Aleem, E. AU - Larsson, O. PY - 2017 DA - 2017// TI - Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage JO - J Biol Chem VL - 292 UR - https://doi.org/10.1074/jbc.M117.781492 DO - 10.1074/jbc.M117.781492 ID - Waraky2017 ER - TY - JOUR AU - Warsito, D. AU - Lin, Y. AU - Gnirck, A. C. AU - Sehat, B. AU - Larsson, O. PY - 2016 DA - 2016// TI - Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.9785 DO - 10.18632/oncotarget.9785 ID - Warsito2016 ER - TY - JOUR AU - Heskamp, S. AU - Boerman, O. C. AU - Molkenboer-Kuenen, J. D. AU - Wauters, C. A. AU - Strobbe, L. J. AU - Mandigers, C. M. PY - 2015 DA - 2015// TI - Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0117745 DO - 10.1371/journal.pone.0117745 ID - Heskamp2015 ER - TY - JOUR AU - Chitnis, M. M. AU - Lodhia, K. A. AU - Aleksic, T. AU - Gao, S. AU - Protheroe, A. S. AU - Macaulay, V. M. PY - 2014 DA - 2014// TI - IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination JO - Oncogene. VL - 33 UR - https://doi.org/10.1038/onc.2013.460 DO - 10.1038/onc.2013.460 ID - Chitnis2014 ER - TY - JOUR AU - Szymonowicz, K. AU - Oeck, S. AU - Krysztofiak, A. AU - Linden, J. AU - Iliakis, G. AU - Jendrossek, V. PY - 2018 DA - 2018// TI - Restraining Akt1 phosphorylation attenuates the repair of radiation-induced DNA double-strand breaks and reduces the survival of irradiated cancer cells JO - Int J Mol Sci VL - 19 UR - https://doi.org/10.3390/ijms19082233 DO - 10.3390/ijms19082233 ID - Szymonowicz2018 ER - TY - JOUR AU - Chen, Y. H. AU - Wang, C. W. AU - Wei, M. F. AU - Tzeng, Y. S. AU - Lan, K. H. AU - Cheng, A. L. PY - 2019 DA - 2019// TI - Maintenance BEZ235 treatment prolongs the therapeutic effect of the combination of BEZ235 and radiotherapy for colorectal cancer JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11081204 DO - 10.3390/cancers11081204 ID - Chen2019 ER - TY - JOUR AU - Lodhia, K. A. AU - Gao, S. AU - Aleksic, T. AU - Esashi, F. AU - Macaulay, V. M. PY - 2015 DA - 2015// TI - Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29327 DO - 10.1002/ijc.29327 ID - Lodhia2015 ER - TY - JOUR AU - O’Flanagan, C. H. AU - O’Shea, S. AU - Lyons, A. AU - Fogarty, F. M. AU - McCabe, N. AU - Kennedy, R. D. PY - 2016 DA - 2016// TI - IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.10862 DO - 10.18632/oncotarget.10862 ID - O’Flanagan2016 ER - TY - JOUR AU - Ferté, C. AU - Loriot, Y. AU - Clémenson, C. AU - Commo, F. AU - Gombos, A. AU - Bibault, J. E. PY - 2013 DA - 2013// TI - IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-1067 DO - 10.1158/1535-7163.MCT-12-1067 ID - Ferté2013 ER - TY - JOUR AU - Flanigan, S. A. AU - Pitts, T. M. AU - Eckhardt, S. G. AU - Tentler, J. J. AU - Tan, A. C. AU - Thorburn, A. PY - 2010 DA - 2010// TI - The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-2054 DO - 10.1158/1078-0432.CCR-10-2054 ID - Flanigan2010 ER - TY - JOUR AU - Zeng, X. AU - Zhang, H. AU - Oh, A. AU - Zhang, Y. AU - Yee, D. PY - 2012 DA - 2012// TI - Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-011-1713-x DO - 10.1007/s10549-011-1713-x ID - Zeng2012 ER - TY - JOUR AU - Beauchamp, M. C. AU - Knafo, A. AU - Yasmeen, A. AU - Carboni, J. M. AU - Gottardis, M. M. AU - Pollak, M. N. PY - 2009 DA - 2009// TI - BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide JO - Gynecol Oncol VL - 115 UR - https://doi.org/10.1016/j.ygyno.2009.07.009 DO - 10.1016/j.ygyno.2009.07.009 ID - Beauchamp2009 ER - TY - JOUR AU - Singh, R. K. AU - Gaikwad, S. M. AU - Jinager, A. AU - Chaudhury, S. AU - Maheshwari, A. AU - Ray, P. PY - 2014 DA - 2014// TI - IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells JO - Cancer Lett VL - 354 UR - https://doi.org/10.1016/j.canlet.2014.08.023 DO - 10.1016/j.canlet.2014.08.023 ID - Singh2014 ER - TY - JOUR AU - Ramcharan, R. AU - Aleksic, T. AU - Kamdoum, W. P. AU - Gao, S. AU - Pfister, S. X. AU - Tanner, J. PY - 2015 DA - 2015// TI - IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.5631 DO - 10.18632/oncotarget.5631 ID - Ramcharan2015 ER - TY - JOUR AU - Dallas, N. A. AU - Xia, L. AU - Fan, F. AU - Gray, M. J. AU - Gaur, P. AU - Buren, G. PY - 2009 DA - 2009// TI - Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2023 DO - 10.1158/0008-5472.CAN-08-2023 ID - Dallas2009 ER - TY - JOUR AU - Camblin, A. J. AU - Pace, E. A. AU - Adams, S. AU - Curley, M. D. AU - Rimkunas, V. AU - Nie, L. PY - 2018 DA - 2018// TI - Dual Inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and Nab-paclitaxel in preclinical models of pancreatic cancer JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-2262 DO - 10.1158/1078-0432.CCR-17-2262 ID - Camblin2018 ER - TY - JOUR AU - Kuhn, D. J. AU - Berkova, Z. AU - Jones, R. J. AU - Woessner, R. AU - Bjorklund, C. C. AU - Ma, W. PY - 2012 DA - 2012// TI - Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2011-10-386789 DO - 10.1182/blood-2011-10-386789 ID - Kuhn2012 ER - TY - JOUR AU - Vaira, V. AU - Lee, C. W. AU - Goel, H. L. AU - Bosari, S. AU - Languino, L. R. AU - Altieri, D. C. PY - 2007 DA - 2007// TI - Regulation of survivin expression by IGF-1/mTOR signaling JO - Oncogene. VL - 26 UR - https://doi.org/10.1038/sj.onc.1210094 DO - 10.1038/sj.onc.1210094 ID - Vaira2007 ER - TY - JOUR AU - Fox, E. M. AU - Miller, T. W. AU - Balko, J. M. AU - Kuba, M. G. AU - Sánchez, V. AU - Smith, R. A. PY - 2011 DA - 2011// TI - A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-1295 DO - 10.1158/0008-5472.CAN-11-1295 ID - Fox2011 ER - TY - JOUR AU - Fox, E. M. AU - Kuba, M. G. AU - Miller, T. W. AU - Davies, B. R. AU - Arteaga, C. L. PY - 2013 DA - 2013// TI - Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation JO - Breast Cancer Res VL - 15 UR - https://doi.org/10.1186/bcr3449 DO - 10.1186/bcr3449 ID - Fox2013 ER - TY - STD TI - Choi HJ, Joo HS, Won HY, Min KW, Kim HY, Son T, et al. Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2018;110. https://doi.org/10.1093/jnci/djx207. ID - ref109 ER - TY - JOUR AU - Chakraborty, A. AU - Hatzis, C. AU - DiGiovanna, M. P. PY - 2017 DA - 2017// TI - Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease JO - Breast Cancer Res Treat VL - 163 UR - https://doi.org/10.1007/s10549-017-4169-9 DO - 10.1007/s10549-017-4169-9 ID - Chakraborty2017 ER - TY - JOUR AU - Locke, J. A. AU - Guns, E. S. AU - Lehman, M. L. AU - Ettinger, S. AU - Zoubeidi, A. AU - Lubik, A. PY - 2010 DA - 2010// TI - Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance JO - Prostate. VL - 70 ID - Locke2010 ER - TY - JOUR AU - Lubik, A. A. AU - Gunter, J. H. AU - Hollier, B. G. AU - Ettinger, S. AU - Fazli, L. AU - Stylianou, N. PY - 2013 DA - 2013// TI - IGF2 increases de novo steroidogenesis in prostate cancer cells JO - Endocr Relat Cancer VL - 20 UR - https://doi.org/10.1530/ERC-12-0250 DO - 10.1530/ERC-12-0250 ID - Lubik2013 ER - TY - JOUR AU - Fahrenholtz, C. D. AU - Beltran, P. J. AU - Burnstein, K. L. PY - 2013 DA - 2013// TI - Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-0648 DO - 10.1158/1535-7163.MCT-12-0648 ID - Fahrenholtz2013 ER - TY - JOUR AU - Wang, X. AU - Huang, Y. AU - Christie, A. AU - Bowden, M. AU - Lee, G. S. AU - Kantoff, P. W. PY - 2015 DA - 2015// TI - Cabozantinib inhibits abiraterone’s upregulation of IGFIR phosphorylation and enhances its anti-prostate cancer activity JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0824 DO - 10.1158/1078-0432.CCR-15-0824 ID - Wang2015 ER - TY - JOUR AU - Nordstrand, A. AU - Bergström, S. H. AU - Thysell, E. AU - Bovinder-Ylitalo, E. AU - Lerner, U. H. AU - Widmark, A. PY - 2017 DA - 2017// TI - Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone JO - Clin Exp Metastasis VL - 34 UR - https://doi.org/10.1007/s10585-017-9848-8 DO - 10.1007/s10585-017-9848-8 ID - Nordstrand2017 ER - TY - JOUR AU - Jia, Y. AU - Zhang, Y. AU - Qiao, C. AU - Liu, G. AU - Zhao, Q. AU - Zhou, T. PY - 2013 DA - 2013// TI - IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model JO - Biochem Biophys Res Commun VL - 436 UR - https://doi.org/10.1016/j.bbrc.2013.06.030 DO - 10.1016/j.bbrc.2013.06.030 ID - Jia2013 ER - TY - JOUR AU - Codony-Servat, J. AU - Cuatrecasas, M. AU - Asensio, E. AU - Montironi, C. AU - Martínez-Cardús, A. AU - Marín-Aguilera, M. PY - 2017 DA - 2017// TI - Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer JO - Br J Cancer VL - 117 UR - https://doi.org/10.1038/bjc.2017.279 DO - 10.1038/bjc.2017.279 ID - Codony-Servat2017 ER - TY - JOUR AU - Ma, Y. AU - Tang, N. AU - Thompson, R. C. AU - Mobley, B. C. AU - Clark, S. W. AU - Sarkaria, J. N. PY - 2016 DA - 2016// TI - InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1677 DO - 10.1158/1078-0432.CCR-15-1677 ID - Ma2016 ER - TY - JOUR AU - Vaquero, J. AU - Lobe, C. AU - Tahraoui, S. AU - Clapéron, A. AU - Mergey, M. AU - Merabtene, F. PY - 2018 DA - 2018// TI - The IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-3725 DO - 10.1158/1078-0432.CCR-17-3725 ID - Vaquero2018 ER - TY - JOUR AU - Vitiello, P. P. AU - Cardone, C. AU - Martini, G. AU - Ciardiello, D. AU - Belli, V. AU - Matrone, N. PY - 2019 DA - 2019// TI - Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-019-1035-0 DO - 10.1186/s13046-019-1035-0 ID - Vitiello2019 ER - TY - JOUR AU - Sanderson, M. P. AU - Hofmann, M. H. AU - Garin-Chesa, P. AU - Schweifer, N. AU - Wernitznig, A. AU - Fischer, S. PY - 2017 DA - 2017// TI - The IGF1R/INSR inhibitor BI 885578 selectively inhibits growth of IGF2-overexpressing colorectal cancer tumors and potentiates the efficacy of anti-VEGF therapy JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0336 DO - 10.1158/1535-7163.MCT-17-0336 ID - Sanderson2017 ER - TY - JOUR AU - Tovar, V. AU - Cornella, H. AU - Moeini, A. AU - Vidal, S. AU - Hoshida, Y. AU - Sia, D. PY - 2017 DA - 2017// TI - Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma JO - Gut. VL - 66 UR - https://doi.org/10.1136/gutjnl-2015-309501 DO - 10.1136/gutjnl-2015-309501 ID - Tovar2017 ER - TY - JOUR AU - Merino, V. F. AU - Cho, S. AU - Liang, X. AU - Park, S. AU - Jin, K. AU - Chen, Q. PY - 2017 DA - 2017// TI - Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors JO - Mol Oncol VL - 11 UR - https://doi.org/10.1002/1878-0261.12053 DO - 10.1002/1878-0261.12053 ID - Merino2017 ER - TY - JOUR AU - Huo, X. AU - Liu, S. AU - Shao, T. AU - Hua, H. AU - Kong, Q. AU - Wang, J. PY - 2014 DA - 2014// TI - GSK3 protein positively regulates type I insulin-like growth factor receptor through forkhead transcription factors FOXO1/3/4 JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M114.580738 DO - 10.1074/jbc.M114.580738 ID - Huo2014 ER - TY - JOUR AU - Scheffold, A. AU - Jebaraj, B. M. C. AU - Tausch, E. AU - Bloehdorn, J. AU - Ghia, P. AU - Yahiaoui, A. PY - 2019 DA - 2019// TI - IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia JO - Blood. VL - 134 UR - https://doi.org/10.1182/blood.2018881029 DO - 10.1182/blood.2018881029 ID - Scheffold2019 ER - TY - JOUR AU - Leroy, C. AU - Ramos, P. AU - Cornille, K. AU - Bonenfant, D. AU - Fritsch, C. AU - Voshol, H. PY - 2016 DA - 2016// TI - Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0697-1 DO - 10.1186/s13058-016-0697-1 ID - Leroy2016 ER - TY - JOUR AU - Zorea, J. AU - Prasad, M. AU - Cohen, L. AU - Elkabets, M. AU - Karabchevsky, A. PY - 2018 DA - 2018// TI - IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer JO - Cell Death Dis VL - 9 UR - https://doi.org/10.1038/s41419-018-1025-8 DO - 10.1038/s41419-018-1025-8 ID - Zorea2018 ER - TY - JOUR AU - Yoon, S. O. AU - Shin, S. AU - Karreth, F. A. AU - Buel, G. R. AU - Jedrychowski, M. P. AU - Plas, D. R. PY - 2017 DA - 2017// TI - Focal adhesion- and IGF1R-dependent survival and migratory pathways mediate tumor resistance to mTORC1/2 inhibition JO - Mol Cell VL - 67 UR - https://doi.org/10.1016/j.molcel.2017.06.033 DO - 10.1016/j.molcel.2017.06.033 ID - Yoon2017 ER - TY - JOUR AU - Lamhamedi-Cherradi, S. E. AU - Menegaz, B. A. AU - Ramamoorthy, V. AU - Vishwamitra, D. AU - Wang, Y. AU - Maywald, R. L. PY - 2016 DA - 2016// TI - IGF-1R and mTOR blockade: novel resistance mechanisms and synergistic drug combinations for Ewing sarcoma JO - J Natl Cancer Inst VL - 108 UR - https://doi.org/10.1093/jnci/djw182 DO - 10.1093/jnci/djw182 ID - Lamhamedi-Cherradi2016 ER - TY - JOUR AU - Benito-Jardón, L. AU - Díaz-Martínez, M. AU - Arellano-Sánchez, N. AU - Vaquero-Morales, P. AU - Esparís-Ogando, A. AU - Teixidó, J. PY - 2019 DA - 2019// TI - Resistance to MAPK inhibitors in melanoma involves activation of the IGF1R-MEK5-Erk5 pathway JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-2762 DO - 10.1158/0008-5472.CAN-18-2762 ID - Benito-Jardón2019 ER - TY - JOUR AU - Strub, T. AU - Ghiraldini, F. G. AU - Carcamo, S. AU - Li, M. AU - Wroblewska, A. AU - Singh, R. PY - 2018 DA - 2018// TI - SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-05966-z DO - 10.1038/s41467-018-05966-z ID - Strub2018 ER - TY - JOUR AU - Guenther, L. M. AU - Dharia, N. V. AU - Ross, L. AU - Conway, A. AU - Robichaud, A. L. AU - Catlett, J. L. PY - 2019 DA - 2019// TI - A combination CDK4/6 and IGF1R inhibitor strategy for Ewing sarcoma JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-0372 DO - 10.1158/1078-0432.CCR-18-0372 ID - Guenther2019 ER - TY - JOUR AU - Isozaki, H. AU - Ichihara, E. AU - Takigawa, N. AU - Ohashi, K. AU - Ochi, N. AU - Yasugi, M. PY - 2016 DA - 2016// TI - Non-small cell lung cancer cells acquire resistance to the ALK Inhibitor alectinib by activating alternative receptor tyrosine kinases JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-15-1010 DO - 10.1158/0008-5472.CAN-15-1010 ID - Isozaki2016 ER - TY - JOUR AU - George, B. AU - George, S. K. AU - Shi, W. AU - Haque, A. AU - Shi, P. AU - Eskandari, G. PY - 2019 DA - 2019// TI - Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0768-8 DO - 10.1186/s13045-019-0768-8 ID - George2019 ER - TY - JOUR AU - Lovly, C. M. AU - McDonald, N. T. AU - Chen, H. AU - Ortiz-Cuaran, S. AU - Heukamp, L. C. AU - Yan, Y. PY - 2014 DA - 2014// TI - Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer JO - Nat Med VL - 20 UR - https://doi.org/10.1038/nm.3667 DO - 10.1038/nm.3667 ID - Lovly2014 ER - TY - JOUR AU - Xu, Y. AU - Vakoc, C. R. PY - 2017 DA - 2017// TI - Targeting cancer cells with BET bromodomain inhibitors JO - Cold Spring Harb Perspect Med VL - 7 UR - https://doi.org/10.1101/cshperspect.a026674 DO - 10.1101/cshperspect.a026674 ID - Xu2017 ER - TY - JOUR AU - Li, W. AU - Gupta, S. K. AU - Han, W. AU - Kundson, R. A. AU - Nelson, S. AU - Knutson, D. PY - 2019 DA - 2019// TI - Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0761-2 DO - 10.1186/s13045-019-0761-2 ID - Li2019 ER - TY - JOUR AU - Stuhlmiller, T. J. AU - Miller, S. M. AU - Zawistowski, J. S. AU - Nakamura, K. AU - Beltran, A. S. AU - Duncan, J. S. PY - 2015 DA - 2015// TI - Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains JO - Cell Rep VL - 11 UR - https://doi.org/10.1016/j.celrep.2015.03.037 DO - 10.1016/j.celrep.2015.03.037 ID - Stuhlmiller2015 ER - TY - JOUR AU - Loganathan, S. N. AU - Tang, N. AU - Holler, A. E. AU - Wang, N. AU - Wang, J. PY - 2019 DA - 2019// TI - Targeting the IGF1R/PI3K/AKT pathway sensitizes Ewing sarcoma to BET bromodomain inhibitors JO - Mol Cancer Ther VL - 18 UR - https://doi.org/10.1158/1535-7163.MCT-18-1151 DO - 10.1158/1535-7163.MCT-18-1151 ID - Loganathan2019 ER - TY - JOUR AU - Kim, K. H. AU - Roberts, C. W. PY - 2016 DA - 2016// TI - Targeting EZH2 in cancer JO - Nat Med VL - 22 UR - https://doi.org/10.1038/nm.4036 DO - 10.1038/nm.4036 ID - Kim2016 ER - TY - JOUR AU - Kleer, C. G. AU - Cao, Q. AU - Varambally, S. AU - Shen, R. AU - Ota, I. AU - Tomlins, S. A. PY - 2003 DA - 2003// TI - EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells JO - Proc Natl Acad Sci U S A VL - 100 UR - https://doi.org/10.1073/pnas.1933744100 DO - 10.1073/pnas.1933744100 ID - Kleer2003 ER - TY - JOUR AU - Li, B. AU - Chng, W. J. PY - 2019 DA - 2019// TI - EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0814-6 DO - 10.1186/s13045-019-0814-6 ID - Li2019 ER - TY - JOUR AU - Bisserier, M. AU - Wajapeyee, N. PY - 2018 DA - 2018// TI - Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-08-804344 DO - 10.1182/blood-2017-08-804344 ID - Bisserier2018 ER - TY - JOUR AU - Tap, W. D. AU - Demetri, G. AU - Barnette, P. AU - Desai, J. AU - Kavan, P. AU - Tozer, R. PY - 2012 DA - 2012// TI - Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.2359 DO - 10.1200/JCO.2011.37.2359 ID - Tap2012 ER - TY - JOUR AU - Cutsem, E. AU - Eng, C. AU - Nowara, E. AU - Swieboda-Sadlej, A. AU - Tebbutt, N. C. AU - Mitchell, E. PY - 2014 DA - 2014// TI - Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumabversus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2752 DO - 10.1158/1078-0432.CCR-13-2752 ID - Cutsem2014 ER - TY - JOUR AU - Fuchs, C. S. AU - Azevedo, S. AU - Okusaka, T. AU - Laethem, J. -. L. AU - Lipton, L. R. AU - Riess, H. PY - 2015 DA - 2015// TI - A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv027 DO - 10.1093/annonc/mdv027 ID - Fuchs2015 ER - TY - JOUR AU - Juergens, H. AU - Daw, N. C. AU - Geoerger, B. AU - Ferrari, S. AU - Villarroel, M. AU - Aerts, I. PY - 2011 DA - 2011// TI - Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.0670 DO - 10.1200/JCO.2010.33.0670 ID - Juergens2011 ER - TY - JOUR AU - Olmos, D. AU - Postel-Vinay, S. AU - Molife, L. R. AU - Okuno, S. H. AU - Schuetze, S. M. AU - Paccagnella, M. L. PY - 2010 DA - 2010// TI - Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70354-7 DO - 10.1016/S1470-2045(09)70354-7 ID - Olmos2010 ER - TY - JOUR AU - Malempati, S. AU - Weigel, B. AU - Ingle, A. M. AU - Ahern, C. H. AU - Carroll, J. M. AU - Roberts, C. T. PY - 2012 DA - 2012// TI - Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.4355 DO - 10.1200/JCO.2011.37.4355 ID - Malempati2012 ER - TY - JOUR AU - Schöffski, P. AU - Adkins, D. AU - Blay, J. Y. AU - Gil, T. AU - Elias, A. D. AU - Rutkowski, P. PY - 2013 DA - 2013// TI - An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2013.06.010 DO - 10.1016/j.ejca.2013.06.010 ID - Schöffski2013 ER - TY - JOUR AU - Abdel-Wahab, R. AU - Varadhachary, G. R. AU - Bhosale, P. R. AU - Wang, X. AU - Fogelman, D. R. AU - Shroff, R. T. PY - 2018 DA - 2018// TI - Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0616-2 DO - 10.1186/s13045-018-0616-2 ID - Abdel-Wahab2018 ER - TY - JOUR AU - Ramalingam, S. S. AU - Spigel, D. R. AU - Chen, D. AU - Steins, M. B. AU - Engelman, J. A. AU - Schneider, C. P. PY - 2011 DA - 2011// TI - Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.36.6799 DO - 10.1200/JCO.2011.36.6799 ID - Ramalingam2011 ER - TY - JOUR AU - Sclafani, F. AU - Kim, T. Y. AU - Cunningham, D. AU - Kim, T. W. AU - Tabernero, J. AU - Schmoll, H. J. PY - 2015 DA - 2015// TI - A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer JO - J Natl Cancer Inst VL - 107 UR - https://doi.org/10.1093/jnci/djv258 DO - 10.1093/jnci/djv258 ID - Sclafani2015 ER - TY - JOUR AU - Maldegem, A. M. AU - Bovée, J. V. AU - Peterse, E. F. AU - Hogendoorn, P. C. AU - Gelderblom, H. PY - 2016 DA - 2016// TI - Ewing sarcoma: the clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway JO - Eur J Cancer VL - 53 UR - https://doi.org/10.1016/j.ejca.2015.09.009 DO - 10.1016/j.ejca.2015.09.009 ID - Maldegem2016 ER - TY - STD TI - Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020:e196650. ID - ref155 ER - TY - JOUR AU - Haluska, P. AU - Menefee, M. AU - Plimack, E. R. AU - Rosenberg, J. AU - Northfelt, D. AU - LaVallee, T. PY - 2014 DA - 2014// TI - Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-0114 DO - 10.1158/1078-0432.CCR-14-0114 ID - Haluska2014 ER - TY - JOUR AU - Iguchi, H. AU - Nishina, T. AU - Nogami, N. AU - Kozuki, T. AU - Yamagiwa, Y. AU - Yagawa, K. PY - 2015 DA - 2015// TI - Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours JO - Investig New Drugs VL - 33 UR - https://doi.org/10.1007/s10637-014-0170-x DO - 10.1007/s10637-014-0170-x ID - Iguchi2015 ER - TY - JOUR AU - Fassnacht, M. AU - Berruti, A. AU - Baudin, E. AU - Demeure, M. J. AU - Gilbert, J. AU - Haak, H. AU - Kroiss, M. PY - 2015 DA - 2015// TI - Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70081-1 DO - 10.1016/S1470-2045(15)70081-1 ID - Fassnacht2015 ER - TY - JOUR AU - Chiappori, A. A. AU - Otterson, G. A. AU - Dowlati, A. AU - Traynor, A. M. AU - Horn, L. AU - Owonikoko, T. K. PY - 2016 DA - 2016// TI - A randomized phase II study of linsitinib (OSI-906) versus topotecan in patients with relapsed small-cell lung cancer JO - Oncologist. VL - 21 UR - https://doi.org/10.1634/theoncologist.2016-0220 DO - 10.1634/theoncologist.2016-0220 ID - Chiappori2016 ER - TY - JOUR AU - Bendell, J. C. AU - Jones, S. F. AU - Hart, L. AU - Spigel, D. R. AU - Lane, C. M. AU - Earwood, C. PY - 2015 DA - 2015// TI - A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer JO - Investig New Drugs VL - 33 UR - https://doi.org/10.1007/s10637-014-0177-3 DO - 10.1007/s10637-014-0177-3 ID - Bendell2015 ER - TY - JOUR AU - Barata, P. AU - Cooney, M. AU - Tyler, A. AU - Wright, J. AU - Dreicer, R. AU - Garcia, J. A. PY - 2018 DA - 2018// TI - A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC) JO - Investig New Drugs VL - 36 UR - https://doi.org/10.1007/s10637-018-0574-0 DO - 10.1007/s10637-018-0574-0 ID - Barata2018 ER - TY - JOUR AU - Mehren, M. AU - George, S. AU - Heinrich, M. C. AU - Schuetze, S. M. AU - Yap, J. T. AU - Yu, J. Q. PY - 2020 DA - 2020// TI - Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study JO - Clin Cancer Res VL - 26 UR - https://doi.org/10.1158/1078-0432.CCR-19-1069 DO - 10.1158/1078-0432.CCR-19-1069 ID - Mehren2020 ER - TY - JOUR AU - Aiken, R. AU - Axelson, M. AU - Harmenberg, J. AU - Klockare, M. AU - Larsson, O. AU - Wassberg, C. PY - 2017 DA - 2017// TI - Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.20662 DO - 10.18632/oncotarget.20662 ID - Aiken2017 ER - TY - JOUR AU - Holohan, C. AU - Schaeybroeck, S. AU - Longley, D. B. AU - Johnston, P. G. PY - 2013 DA - 2013// TI - Cancer drug resistance: an evolving paradigm JO - Nat Rev Cancer VL - 13 UR - https://doi.org/10.1038/nrc3599 DO - 10.1038/nrc3599 ID - Holohan2013 ER - TY - JOUR AU - Buck, E. AU - Gokhale, P. C. AU - Koujak, S. AU - Brown, E. AU - Eyzaguirre, A. AU - Tao, N. PY - 2010 DA - 2010// TI - Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-10-0318 DO - 10.1158/1535-7163.MCT-10-0318 ID - Buck2010 ER - TY - JOUR AU - Rostoker, R. AU - Abelson, S. AU - Bitton-Worms, K. AU - Genkin, I. AU - Ben-Shmuel, S. AU - Dakwar, M. PY - 2015 DA - 2015// TI - Highly specific role of the insulin receptor in breast cancer progression JO - Endocr Relat Cancer VL - 22 UR - https://doi.org/10.1530/ERC-14-0490 DO - 10.1530/ERC-14-0490 ID - Rostoker2015 ER - TY - JOUR AU - Forest, A. AU - Amatulli, M. AU - Ludwig, D. L. AU - Damoci, C. B. AU - Wang, Y. AU - Burns, C. A. PY - 2015 DA - 2015// TI - Intrinsic resistance to cixutumumab is conferred by distinct isoforms of the insulin receptor JO - Mol Cancer Res VL - 13 UR - https://doi.org/10.1158/1541-7786.MCR-15-0279 DO - 10.1158/1541-7786.MCR-15-0279 ID - Forest2015 ER - TY - JOUR AU - Ulanet, D. B. AU - Ludwig, D. L. AU - Kahn, C. R. AU - Hanahan, D. PY - 2010 DA - 2010// TI - Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0914076107 DO - 10.1073/pnas.0914076107 ID - Ulanet2010 ER - TY - JOUR AU - Garofalo, C. AU - Manara, M. C. AU - Nicoletti, G. AU - Marino, M. T. AU - Lollini, P. L. AU - Astolfi, A. PY - 2011 DA - 2011// TI - Efficacy of and resistance to anti-IGF-1R therapies in Ewing’s sarcoma is dependent on insulin receptor signaling JO - Oncogene. VL - 30 UR - https://doi.org/10.1038/onc.2010.640 DO - 10.1038/onc.2010.640 ID - Garofalo2011 ER - TY - JOUR AU - Seguin, L. AU - Desgrosellier, J. S. AU - Weis, S. M. AU - Cheresh, D. A. PY - 2015 DA - 2015// TI - Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance JO - Trends Cell Biol VL - 25 UR - https://doi.org/10.1016/j.tcb.2014.12.006 DO - 10.1016/j.tcb.2014.12.006 ID - Seguin2015 ER - TY - JOUR AU - Saegusa, J. AU - Yamaji, S. AU - Ieguchi, K. AU - Wu, C. Y. AU - Lam, K. S. AU - Liu, F. T. PY - 2009 DA - 2009// TI - The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling JO - J Biol Chem VL - 284 UR - https://doi.org/10.1074/jbc.M109.013201 DO - 10.1074/jbc.M109.013201 ID - Saegusa2009 ER - TY - JOUR AU - Shin, D. H. AU - Lee, H. J. AU - Min, H. Y. AU - Choi, S. P. AU - Lee, M. S. AU - Lee, J. W. PY - 2013 DA - 2013// TI - Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway JO - J Natl Cancer Inst VL - 105 UR - https://doi.org/10.1093/jnci/djt263 DO - 10.1093/jnci/djt263 ID - Shin2013 ER - TY - JOUR AU - Wan, X. AU - Yeung, C. AU - Heske, C. AU - Mendoza, A. AU - Helman, L. J. PY - 2015 DA - 2015// TI - IGF-1R inhibition activates a YES/SFK bypass resistance pathway: rational basis for co-targeting IGF-1R and Yes/SFK kinase in rhabdomyosarcoma JO - Neoplasia. VL - 17 UR - https://doi.org/10.1016/j.neo.2015.03.001 DO - 10.1016/j.neo.2015.03.001 ID - Wan2015 ER - TY - JOUR AU - Desbois-Mouthon, C. AU - Baron, A. AU - Blivet-Van Eggelpoël, M. J. AU - Fartoux, L. AU - Venot, C. AU - Bladt, F. PY - 2009 DA - 2009// TI - Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-2980 DO - 10.1158/1078-0432.CCR-08-2980 ID - Desbois-Mouthon2009 ER - TY - JOUR AU - Shin, D. H. AU - Min, H. Y. AU - El-Naggar, A. K. AU - Lippman, S. M. AU - Glisson, B. AU - Lee, H. Y. PY - 2011 DA - 2011// TI - Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-11-0235 DO - 10.1158/1535-7163.MCT-11-0235 ID - Shin2011 ER - TY - JOUR AU - Knowlden, J. M. AU - Gee, J. M. AU - Barrow, D. AU - Robertson, J. F. AU - Ellis, I. O. AU - Nicholson, R. I. PY - 2011 DA - 2011// TI - erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines JO - Breast Cancer Res VL - 13 UR - https://doi.org/10.1186/bcr3018 DO - 10.1186/bcr3018 ID - Knowlden2011 ER - TY - JOUR AU - Abraham, J. AU - Prajapati, S. I. AU - Nishijo, K. AU - Schaffer, B. S. AU - Taniguchi, E. AU - Kilcoyne, A. PY - 2011 DA - 2011// TI - Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-10-0695 DO - 10.1158/1535-7163.MCT-10-0695 ID - Abraham2011 ER - TY - JOUR AU - Potratz, J. C. AU - Saunders, D. N. AU - Wai, D. H. AU - Ng, T. L. AU - McKinney, S. E. AU - Carboni, J. M. PY - 2010 DA - 2010// TI - Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-1093 DO - 10.1158/0008-5472.CAN-10-1093 ID - Potratz2010 ER - TY - JOUR AU - Huang, F. AU - Hurlburt, W. AU - Greer, A. AU - Reeves, K. A. AU - Hillerman, S. AU - Chang, H. PY - 2010 DA - 2010// TI - Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-0391 DO - 10.1158/0008-5472.CAN-10-0391 ID - Huang2010 ER - TY - JOUR AU - Heske, C. M. AU - Yeung, C. AU - Mendoza, A. AU - Baumgart, J. T. AU - Edessa, L. D. AU - Wan, X. PY - 2016 DA - 2016// TI - The role of PDGFR-β activation in acquired resistance to IGF-1R blockade in preclinical models of rhabdomyosarcoma JO - Transl Oncol VL - 9 UR - https://doi.org/10.1016/j.tranon.2016.09.002 DO - 10.1016/j.tranon.2016.09.002 ID - Heske2016 ER - TY - JOUR AU - Gvozdenovic, A. AU - Boro, A. AU - Born, W. AU - Muff, R. AU - Fuchs, B. PY - 2017 DA - 2017// TI - A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model JO - Am J Cancer Res VL - 7 ID - Gvozdenovic2017 ER - TY - JOUR AU - Zhao, H. AU - Desai, V. AU - Wang, J. AU - Epstein, D. M. AU - Miglarese, M. AU - Buck, E. PY - 2012 DA - 2012// TI - Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0327 DO - 10.1158/1535-7163.MCT-11-0327 ID - Zhao2012 ER - TY - JOUR AU - Nomura, S. PY - 2019 DA - 2019// TI - Identification, friend or foe: vimentin and α-smooth muscle actin in cancer-associated fibroblasts JO - Ann Surg Oncol VL - 26 UR - https://doi.org/10.1245/s10434-019-07894-8 DO - 10.1245/s10434-019-07894-8 ID - Nomura2019 ER - TY - JOUR AU - Choi, J. AU - Gyamfi, J. AU - Jang, H. AU - Koo, J. S. PY - 2018 DA - 2018// TI - The role of tumor-associated macrophage in breast cancer biology JO - Histol Histopathol VL - 33 ID - Choi2018 ER - TY - JOUR AU - Lin, Y. AU - Xu, J. AU - Lan, H. PY - 2019 DA - 2019// TI - Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0760-3 DO - 10.1186/s13045-019-0760-3 ID - Lin2019 ER - TY - JOUR AU - Ruffell, B. AU - Coussens, L. M. PY - 2015 DA - 2015// TI - Macrophages and therapeutic resistance in cancer JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.02.015 DO - 10.1016/j.ccell.2015.02.015 ID - Ruffell2015 ER - TY - JOUR AU - Ireland, L. AU - Santos, A. AU - Ahmed, M. S. AU - Rainer, C. AU - Nielsen, S. R. AU - Quaranta, V. PY - 2016 DA - 2016// TI - Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-16-1201 DO - 10.1158/0008-5472.CAN-16-1201 ID - Ireland2016 ER - TY - JOUR AU - Tommelein, J. AU - Vlieghere, E. AU - Verset, L. AU - Melsens, E. AU - Leenders, J. AU - Descamps, B. PY - 2018 DA - 2018// TI - Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation JO - Cancer Res VL - 78 UR - https://doi.org/10.1158/0008-5472.CAN-17-0524 DO - 10.1158/0008-5472.CAN-17-0524 ID - Tommelein2018 ER - TY - JOUR AU - Triplett, T. A. AU - Cardenas, K. T. AU - Lancaster, J. N. AU - Hu, Z. AU - Selden, H. J. AU - Jasso, G. J. PY - 2016 DA - 2016// TI - Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation JO - Proc Natl Acad Sci U S A VL - 113 UR - https://doi.org/10.1073/pnas.1520245113 DO - 10.1073/pnas.1520245113 ID - Triplett2016 ER - TY - JOUR AU - Lee, J. S. AU - Kang, J. H. AU - Boo, H. J. AU - Hwang, S. J. AU - Hong, S. AU - Lee, S. C. PY - 2015 DA - 2015// TI - STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms9499 DO - 10.1038/ncomms9499 ID - Lee2015 ER - TY - JOUR AU - Leonetti, A. AU - Sharma, S. AU - Minari, R. AU - Perego, P. AU - Giovannetti, E. AU - Tiseo, M. PY - 2019 DA - 2019// TI - Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer JO - Br J Cancer VL - 121 UR - https://doi.org/10.1038/s41416-019-0573-8 DO - 10.1038/s41416-019-0573-8 ID - Leonetti2019 ER - TY - JOUR AU - Lee, H. AU - Kim, N. AU - Yoo, Y. J. AU - Kim, H. AU - Jeong, E. AU - Choi, S. PY - 2018 DA - 2018// TI - β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer JO - Oncogene. VL - 37 UR - https://doi.org/10.1038/s41388-018-0362-5 DO - 10.1038/s41388-018-0362-5 ID - Lee2018 ER - TY - JOUR AU - Oh, S. C. AU - Sohn, B. H. AU - Cheong, J. H. AU - Kim, S. B. AU - Lee, J. E. AU - Park, K. C. PY - 2018 DA - 2018// TI - Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-04179-8 DO - 10.1038/s41467-018-04179-8 ID - Oh2018 ER - TY - JOUR AU - Cohen-Sinai, T. AU - Cohen, Z. AU - Werner, H. AU - Berger, R. PY - 2017 DA - 2017// TI - Identification of BRCA1 as a potential biomarker for insulin-like growth factor-1 receptor targeted therapy in breast cancer JO - Front Endocrinol (Lausanne) VL - 8 UR - https://doi.org/10.3389/fendo.2017.00148 DO - 10.3389/fendo.2017.00148 ID - Cohen-Sinai2017 ER - TY - JOUR AU - Trautmann, M. AU - Menzel, J. AU - Bertling, C. AU - Cyra, M. AU - Cyra, M. AU - Isfort, I. PY - 2017 DA - 2017// TI - FUS-DDIT3 fusion protein-driven IGF-IR signaling is a therapeutic target in myxoid liposarcoma JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0130 DO - 10.1158/1078-0432.CCR-17-0130 ID - Trautmann2017 ER - TY - JOUR AU - Mancarella, C. AU - Casanova-Salas, I. AU - Calatrava, A. AU - Ventura, S. AU - Garofalo, C. AU - Rubio-Briones, J. PY - 2015 DA - 2015// TI - ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.3425 DO - 10.18632/oncotarget.3425 ID - Mancarella2015 ER - TY - JOUR AU - Huang, F. AU - Chang, H. AU - Greer, A. AU - Hillerman, S. AU - Reeves, K. A. AU - Hurlburt, W. PY - 2015 DA - 2015// TI - IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-14-0794-T DO - 10.1158/1535-7163.MCT-14-0794-T ID - Huang2015 ER - TY - JOUR AU - Patel, M. AU - Gomez, N. C. AU - McFadden, A. W. AU - Moats-Staats, B. M. AU - Wu, S. AU - Rojas, A. PY - 2014 DA - 2014// TI - PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition JO - Mol Cancer Res VL - 12 UR - https://doi.org/10.1158/1541-7786.MCR-14-0006 DO - 10.1158/1541-7786.MCR-14-0006 ID - Patel2014 ER - TY - JOUR AU - Wang, Q. AU - Wei, F. AU - Lv, G. AU - Li, C. AU - Liu, T. AU - Hadjipanayis, C. G. PY - 2013 DA - 2013// TI - The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin JO - BMC Cancer VL - 13 UR - https://doi.org/10.1186/1471-2407-13-521 DO - 10.1186/1471-2407-13-521 ID - Wang2013 ER - TY - JOUR AU - Pavlicek, A. AU - Lira, M. E. AU - Lee, N. V. AU - Ching, K. A. AU - Ye, J. AU - Cao, J. PY - 2013 DA - 2013// TI - Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871) JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-13-0442-T DO - 10.1158/1535-7163.MCT-13-0442-T ID - Pavlicek2013 ER - TY - JOUR AU - McCaffery, I. AU - Tudor, Y. AU - Deng, H. AU - Tang, R. AU - Suzuki, S. AU - Badola, S. PY - 2013 DA - 2013// TI - Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-1840 DO - 10.1158/1078-0432.CCR-12-1840 ID - McCaffery2013 ER - TY - JOUR AU - Lee, H. J. AU - Pham, P. C. AU - Hyun, S. Y. AU - Baek, B. AU - Kim, B. AU - Kim, Y. PY - 2018 DA - 2018// TI - Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0802-4 DO - 10.1186/s12943-018-0802-4 ID - Lee2018 ER - TY - JOUR AU - Kuenzi, B. M. AU - Remsing Rix, L. L. AU - Stewart, P. A. AU - Fang, B. AU - Kinose, F. AU - Bryant, A. T. PY - 2017 DA - 2017// TI - Polypharmacology-based ceritinib repurposing using integrated functional proteomics JO - Nat Chem Biol VL - 13 UR - https://doi.org/10.1038/nchembio.2489 DO - 10.1038/nchembio.2489 ID - Kuenzi2017 ER - TY - JOUR AU - Russo, A. AU - Paret, C. AU - Alt, F. AU - Burhenne, J. AU - Fresnais, M. AU - Wagner, W. PY - 2019 DA - 2019// TI - Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor JO - Int J Mol Sci VL - 20 UR - https://doi.org/10.3390/ijms20174267 DO - 10.3390/ijms20174267 ID - Russo2019 ER - TY - JOUR AU - Vewinger, N. AU - Huprich, S. AU - Seidmann, L. AU - Russo, A. AU - Alt, F. AU - Bender, H. PY - 2019 DA - 2019// TI - IGF1R is a potential new therapeutic target for HGNET-BCOR brain tumor patients JO - Int J Mol Sci VL - 20 UR - https://doi.org/10.3390/ijms20123027 DO - 10.3390/ijms20123027 ID - Vewinger2019 ER - TY - JOUR AU - Reuveni, H. AU - Flashner-Abramson, E. AU - Steiner, L. AU - Makedonski, K. AU - Song, R. AU - Shir, A. PY - 2013 DA - 2013// TI - Therapeutic destruction of insulin receptor substrates for cancer treatment JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-3385 DO - 10.1158/0008-5472.CAN-12-3385 ID - Reuveni2013 ER - TY - JOUR AU - Ibuki, N. AU - Ghaffari, M. AU - Reuveni, H. AU - Pandey, M. AU - Fazli, L. AU - Azuma, H. PY - 2014 DA - 2014// TI - The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-13-0842 DO - 10.1158/1535-7163.MCT-13-0842 ID - Ibuki2014 ER - TY - JOUR AU - Yang, Y. AU - Chan, J. Y. AU - Temiz, N. A. AU - Yee, D. PY - 2018 DA - 2018// TI - Insulin receptor substrate suppression by the tyrphostin NT157 inhibits responses to insulin-like growth factor-I and insulin in breast cancer cells JO - Horm Cancer VL - 9 UR - https://doi.org/10.1007/s12672-018-0343-8 DO - 10.1007/s12672-018-0343-8 ID - Yang2018 ER - TY - JOUR AU - Janku, F. AU - Huang, H. J. AU - Angelo, L. S. AU - Kurzrock, R. PY - 2013 DA - 2013// TI - A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): implications for inhibition of the IGF-1R signal JO - Oncotarget. VL - 4 UR - https://doi.org/10.18632/oncotarget.886 DO - 10.18632/oncotarget.886 ID - Janku2013 ER - TY - JOUR AU - Pian, L. AU - Wen, X. AU - Kang, L. AU - Li, Z. AU - Nie, Y. AU - Du, Z. PY - 2018 DA - 2018// TI - Targeting the IGF1R pathway in breast cancer using antisense lncRNA-mediated promoter cis competition JO - Mol Ther Nucleic Acids VL - 12 UR - https://doi.org/10.1016/j.omtn.2018.04.013 DO - 10.1016/j.omtn.2018.04.013 ID - Pian2018 ER - TY - JOUR AU - Kumar, A. S. AU - Rayala, S. K. AU - Venkatraman, G. PY - 2018 DA - 2018// TI - Targeting IGF1R pathway in cancer with microRNAs: How close are we? JO - RNA Biol VL - 15 UR - https://doi.org/10.1080/15476286.2017.1338240 DO - 10.1080/15476286.2017.1338240 ID - Kumar2018 ER -